Thrombotic Microangiopathy in Autopsy-Confirmed Lung Signet Ring Cell Carcinoma

Carlos E. Gonzalez^1, , Luis A. Gonzalez¹, Luis A. Cesenas² and Olga G. Cantu³

¹Departamento de Medicina Interna, Hospital Universitario “José E. González”, Monterrey, México

²Departamento de Patología, Hospital Universitario “José E. González”, Monterrey, México

³Departamento de Hematología, Hospital Universitario “José E. González”, Monterrey, México

Cite this paper

Carlos E. Gonzalez, Luis A. Gonzalez, Luis A. Cesenas and Olga G. Cantu. Thrombotic Microangiopathy in Autopsy-Confirmed Lung Signet Ring Cell Carcinoma. American Journal of Medical Case Reports. 2022; 10(2):22-25. doi: 10.12691/AJMCR-10-2-1

Abstract

Thrombotic Microangiopathy (TMA) has been described as a rare paraneoplastic syndrome. We present a patient with Coombs-negative hemolytic anemia and schistocytes in a peripheral blood smear, fulfilling diagnosis criteria for TMA. After patients death, an autopsy report revealed bone infiltrating signet ring cell carcinoma, identifying the lung as the primary tumor origin.

Keywords

Thrombotic microangiopathy, microangiopathic hemolytic anemia, signet ring cell carcinoma, paraneoplastic syndrome, lung cancer

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Weitz IC., “Thrombotic microangiopathy in cancer.” Thromb Res. 2018; 164(2017):S103-S105.
[2]	Bayer G, Von Tokarski F, Thoreau B, et al. “Etiology and outcomes of thrombotic microangiopathies.” Clin J Am Soc Nephrol. 2019; 14(4): 557-566.
[3]	Merchant SH, Amin MB, Tamboli P, et al. “Primary signet-ring cell carcinoma of lung: Immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas.” Am J Surg Pathol. 2001; 25(12): 1515-1519.
[4]	Socola F, Loaiza-Bonilla A, Bustinza-Linares E, Correa R, Rosenblatt JD. “Recurrent Thrombotic Thrombocytopenic Purpura-Like Syndrome as a Paraneoplastic Phenomenon in Malignant Peritoneal Mesothelioma: A Case Report and Review of the Literature.” Case Rep Oncol Med. 2012; 2012: 1-5.
[5]	Gainza E, Fernández S, Martínez D, et al. “Pulmonary tumor thrombotic microangiopathy: Report of 3 cases and review of the literature.” Med (United States). 2014; 93(24): 359-363.
[6]	Shih HM, Lin CC, Shiao YW. “Pulmonary tumor thrombotic microangiopathy.” Am J Emerg Med. 2011; 29(2): 241. e3-241.e4.
[7]	Dorothea H, Erxleben C. “Pulmonale tumorthrombotische Mikroangiopathie bei einer Patientin mit metastasierendem Magenkarzinom Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Metastatic Gastric Cancer” Einleitung Therapie und Verlauf Anamnese Befunde und Untersuchungen. DMW - Dtsch Medizinische Wochenschrift. Published online 2018.
[8]	Morita S, Kamimura K, Abe H, et al. “Pulmonary tumor thrombotic microangiopathy of hepatocellular carcinoma: A case report and review of literature.” World J Gastroenterol. 2019; 25(48): 6949-6958.
[9]	Katayama S, Takenaka T, Nakamura A, Sako S, Bessho A, Ohara N. “Pulmonary tumor thrombotic microangiopathy induced by prostate cancer.” Acta Med Okayama. 2018; 72(3): 309-313.
[10]	Imakura T, Tezuka T, Inayama M, et al. “A long-term survival case of pulmonary tumor thrombotic microangiopathy due to gastric cancer confirmed by the early diagnosis based on a transbronchial lung biopsy.” Intern Med. 2020; 59(13): 1621-1627.
[11]	Eisa N, Nasef K, Emarah Z, Fattah MMA, Shamaa S. “A Metastatic Signet Ring Cell Carcinoma Presented as Acquired Thrombotic Thrombocytopenic Purpura: A Case Report”. J Hematol. 2018;7(2): 72-75.
[12]	Malkan UY, Albayrak M, Ozturk HB, Reis Aras M, Saglam B, Dogan K. “A Signet Ring Cell Carcinoma Presented as Refractory Acquired Thrombotic Thrombocytopenic Purpura. Case Rep Oncol.” Published online 2020: 1368-1372.
[13]	Otrock ZK, Taher AT, Makarem JA, Kattar MM, Nsouli G, Shamseddine AI. “Thrombotic thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer.” Dig Dis Sci. 2007; 52(6): 1589-1591.